Advertisement

Current Problems in Quantitative Structure Activity Relationships

  • Hugo Kubinyi
Conference paper

Abstract

Quantitative structure activity relationships (QSAR) are to be understood as a consequence of the fact that the interactions of drugs with their biological counterparts are determined by intermolecular forces. Thus the structural dependence of biological activities can be described either by physicochemical parameters (Hansch analysis) or by indicator variables encoding different structural features (Free Wilson analysis, pattern recognition).

Keywords

Quantitative Structure Activity Relationship Quantitative Structure Activity Relationship Bilinear Model Parabolic Model Enzyme Inhibitor Complex 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    S. M. Free, Jr. and J. W. Wilson, J. Med. Chem. 7, 395 - 9 (1964)CrossRefGoogle Scholar
  2. [2]
    C. Hansch and T. Fujita, J. Amer. Chem. Soc. 86, 1616 - 26 (1964)CrossRefGoogle Scholar
  3. [3]
    J. D. P. Graham and M. A. Karrar, J. Med. Chem. 6, 103–7 (1963)CrossRefGoogle Scholar
  4. [4]
    H. Kubinyi and O.-H. Kehrhahn, J. Med. Chem. 19, 578–86 (1976)CrossRefGoogle Scholar
  5. [5]
    F. B. Abramson, R. B. Barlow, M. G. Mustafa and R. P. Stephenson, Br. J. Pharmac. 37, 207–33 (1969)Google Scholar
  6. [6]
    H. Kubinyi, in: Comprehensive Medicinal Chemistry, Edited by C. Hansch, Vol. 4, Pergamon Press, Oxford, England, in pressGoogle Scholar
  7. [7]
    7]C. Hansch and J. M. Clayton, J. Pharm. Sci. 62, 1–21 (1973)CrossRefGoogle Scholar
  8. [8]
    J. W. McFarland, J. Med. Chem. 13, 1192–6 (1970)CrossRefGoogle Scholar
  9. [9]
    R. M. Hyde, J. Med. Chem. 18, 231–3 (1975)CrossRefGoogle Scholar
  10. [10]
    H. Kubinyi, J. Med. Chem. 20, 625–9 (1977)CrossRefGoogle Scholar
  11. [11]
    P. B. M. W. M. Timmermans, A. de Jonge, J. C. A. van Meel, F. P. Slothorst-Grisdijk, E. Lam and P. A. van Zwieten, J. Med. Chem. 24, 502–7 (1981)CrossRefGoogle Scholar
  12. [12]
    P. B. M. W. M. Timmermans, A. de Jonge, M. J. M. C. Thoolen, B. Wilffert, H. Batink and P. A. van Zwieten, J. Med. Chem. 27, 495–503 (1984)CrossRefGoogle Scholar
  13. [13]
    R. A. Scherrer and S. M. Howard, J. Med. Chem. 20, 53–8 (1977)CrossRefGoogle Scholar
  14. [14]
    H. Kubinyi, QSAR Des. Bioact. Compd., Edited by M. Kuchar, Prous, Barcelona 1984, Spain, p. 321–46Google Scholar
  15. [15]
    R. A. Scherrer and S. M. Howard, in: Computer-Assisted Drug Design, ACS Symposium Series 112, 507–26 (1979)CrossRefGoogle Scholar
  16. [16]
    K.-J. Schaper, Quant. Struct. Act. Relat. 1, 13–27 (1982)CrossRefGoogle Scholar
  17. [17]
    J. Deisenhofer, O. Epp, K. Miki, R. Huber and H. Michel, Nature 318, 618–24 (1985)CrossRefGoogle Scholar
  18. [18]
    J. M. Blaney, C. Hansch, C. Silipo and A. Vittoria, Chem. Rev. 84, 333–407 (1984)CrossRefGoogle Scholar
  19. [19]
    R.-L. Li, C. Hansch, D. Matthews, J. M. Blaney, R. Langridge, T. J. Delcamp, S. S. Susten and J. H. Freisheim, Quant. Struct., Act. Relat. 1, 1–7 (1982)CrossRefGoogle Scholar
  20. [20]
    L. F. Kuyper, B. Roth, D. P. Baccanari, R. Ferone, C. R. Beddell, J. N. Champness, D. K. Stammers, J. G. Dann, F. E. A. Norrington, D. J. Baker and P. J. Goodford, J. Med. Chem. 25, 1120–2 (1982)CrossRefGoogle Scholar
  21. [21]
    K.-H. Czaplinsky, M. Kansy and J. K. Seydel, Quant. Struct. Act. Relat. 6, 70–72 (1987)CrossRefGoogle Scholar
  22. [22]
    T. L. Poulos and A. J. Howard, Biochemistry 26, 8165–74 (1987)CrossRefGoogle Scholar
  23. [23]
    G. Franckowiak, M. Bechem, M. Schramm and G. Thomas, Eur. J. Pharmacol. 114, 223–6 (1985)CrossRefGoogle Scholar
  24. [24]
    P. M. Dean, Molecular foundations of drug-receptor inter-action, Cambridge University Press, Cambridge 1987, EnglandGoogle Scholar
  25. [25]
    P. J. Goodford, J. Med. Chem. 27, 557–64 (1984)CrossRefGoogle Scholar
  26. [26]
    P. J. Goodford, J. Med. Chem. 28, 849–57 (1985)CrossRefGoogle Scholar
  27. [27]
    C. Hansch and T. E. Klein, Acc. Chem. Res. 19, 392–400 (1986)CrossRefGoogle Scholar
  28. [28]
    G. R. Marshall, Ann. Rev. Pharmacol. Toxicol. 27, 193–213 (1987)CrossRefGoogle Scholar
  29. [29]
    R. L. DesJarlais, R. P. Sheridan, G. L. Seibel, J. S. Dixon, I. D. Kuntz and R. Venkataraghavan, J. Med. Chem. 31, 722–9 (1988)CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • Hugo Kubinyi
    • 1
  1. 1.BASF AGLudwigshafenFederal Republic of Germany

Personalised recommendations